UBS AM’s Editas Medicine EDIT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.19K | Buy |
+480
| New | +$1.02K | ﹤0.01% | 3662 |
|
|
2025
Q2 | – | Sell |
-2,600,000
| Closed | -$3.02M | – | 2646 |
|
|
2025
Q1 | $3.02M | Buy |
2,600,000
+1,430,000
| +122% | +$2.1M | ﹤0.01% | 1810 |
|
|
2024
Q4 | $1.49M | Buy |
1,170,000
+272,467
| +30% | +$694K | ﹤0.01% | 2184 |
|
|
2024
Q3 | $3.06M | Sell |
897,533
-4,090
| -0.5% | -$17.8K | ﹤0.01% | 1813 |
|
|
2024
Q2 | $4.21M | Buy |
901,623
+818,056
| +979% | +$4.61M | ﹤0.01% | 1586 |
|
|
2024
Q1 | $620K | Sell |
83,567
-9,383
| -10% | -$78K | ﹤0.01% | 2218 |
|
|
2023
Q4 | $942K | Hold |
92,950
| – | – | ﹤0.01% | 2054 |
|
|
2023
Q3 | $725K | Buy |
92,950
+19,449
| +26% | +$167K | ﹤0.01% | 2135 |
|
|
2023
Q2 | $533K | Hold |
73,501
| – | – | ﹤0.01% | 2298 |
|
|
2023
Q1 | $533K | Buy |
73,501
+6,822
| +10% | +$60.7K | ﹤0.01% | 2298 |
|
|
2022
Q4 | $591K | Buy |
66,679
+4,648
| +7% | +$51K | ﹤0.01% | 2106 |
|
|
2022
Q3 | $759K | Buy |
62,031
+10,347
| +20% | +$161K | ﹤0.01% | 2126 |
|
|
2022
Q2 | $611K | Sell |
51,684
-11,402
| -18% | -$153K | ﹤0.01% | 2224 |
|
|
2022
Q1 | $1.2M | Hold |
63,086
| – | – | ﹤0.01% | 2037 |
|
|
2021
Q4 | $1.67M | Sell |
63,086
-4,547
| -7% | -$157K | ﹤0.01% | 1954 |
|
|
2021
Q3 | $2.78M | Buy |
67,633
+3,050
| +5% | +$167K | ﹤0.01% | 1683 |
|
|
2021
Q2 | $3.66M | Buy |
64,583
+7,295
| +13% | +$269K | ﹤0.01% | 1532 |
|
|
2021
Q1 | $2.41M | Sell |
57,288
-11,494
| -17% | -$655K | ﹤0.01% | 1681 |
|
|
2020
Q4 | $4.82M | Buy |
68,782
+11,753
| +21% | +$483K | ﹤0.01% | 1312 |
|
|
2020
Q3 | $1.6M | Buy |
57,029
+9,323
| +20% | +$304K | ﹤0.01% | 1641 |
|
|
2020
Q2 | $1.41M | Buy |
47,706
+5,670
| +13% | +$148K | ﹤0.01% | 1660 |
|
|
2020
Q1 | $834K | Buy |
42,036
+14,240
| +51% | +$359K | ﹤0.01% | 1770 |
|
|
2019
Q4 | $823K | Buy |
27,796
+1,327
| +5% | +$33.1K | ﹤0.01% | 2012 |
|
|
2019
Q3 | $602K | Buy |
26,469
+12,069
| +84% | +$299K | ﹤0.01% | 2197 |
|
|
2019
Q2 | $356K | Hold |
14,400
| – | – | ﹤0.01% | 2350 |
|
|
2019
Q1 | $352K | Sell |
14,400
-167,921
| -92% | -$3.8M | ﹤0.01% | 2251 |
|
|
2018
Q4 | $4.15M | Sell |
182,321
-16,172
| -8% | -$440K | ﹤0.01% | 1154 |
|
|
2018
Q3 | $6.32M | Sell |
198,493
-427
| -0.2% | -$13.8K | ﹤0.01% | 1068 |
|
|
2018
Q2 | $7.13M | Buy |
198,920
+37,959
| +24% | +$1.34M | 0.01% | 1036 |
|
|
2018
Q1 | $5.34M | Sell |
160,961
-85,240
| -35% | -$3.04M | ﹤0.01% | 1120 |
|
|
2017
Q4 | $7.57M | Buy |
+246,201
| New | +$6.2M | 0.01% | 989 |
|
Other funds holding EDIT
VCM
VPM
N
OM
UBS AM's EDIT Position: Q1 2026 in Review
UBS AM opened a new position in Editas Medicine (EDIT) in Q1 2026: 480 shares worth $1.19K. The stake represents ﹤0.01% of the portfolio and ranks #3662 among its holdings. This is a return to the name: UBS AM previously reported a position in EDIT as recently as Q1 2025.
UBS AM first reported a position in EDIT in Q4 2017 and has held it in 31 quarters since. The position peaked at $7.57M in Q4 2017. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.
- UBS AM held 480 shares of Editas Medicine worth $1.19K as of Q1 2026.
- Editas Medicine was a new UBS AM position in Q1 2026.
- Editas Medicine made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #3662 holding.
- UBS AM first reported a position in Editas Medicine in Q4 2017 and has held it in 31 quarters since.
- UBS AM's Editas Medicine position peaked at $7.57M in Q4 2017.
- 207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.
Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.